@article{ref1,
title="Daclizumab",
journal="Hospital pharmacy",
year="2016",
author="Kim, A.P. and Baker, D.E.",
volume="51",
number="11",
pages="928-939",
abstract="Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The December 2016 monograph topics are ozenoxacin cream, ocrelizumab, naldemedine, eteplirsen, and abaloparatide. The Safety MUE is on buprenorphine buccal. 2016 © Thomas Land Publishers, Inc.<p /><p>Language: en</p>",
language="en",
issn="0018-5787",
doi="10.1310/hpj5111-928",
url="http://dx.doi.org/10.1310/hpj5111-928"
}